Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 4
2017 3
2020 1
2021 3
2022 1
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Using systems approaches to address challenges for clinical implementation of pharmacogenomics.
Karnes JH, Van Driest S, Bowton EA, Weeke PE, Mosley JD, Peterson JF, Denny JC, Roden DM. Karnes JH, et al. Wiley Interdiscip Rev Syst Biol Med. 2014 Mar-Apr;6(2):125-35. doi: 10.1002/wsbm.1255. Epub 2013 Dec 6. Wiley Interdiscip Rev Syst Biol Med. 2014. PMID: 24319008 Free PMC article. Review.
Many genetic variants have been shown to affect drug response through changes in drug efficacy and likelihood of adverse effects. Much of pharmacogenomic science has focused on discovering and clinically implementing single gene variants with large effect sizes. Giv …
Many genetic variants have been shown to affect drug response through changes in drug efficacy and likelihood of adverse effects. Much of …
Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.
GBD 2021 US Burden of Disease and Forecasting Collaborators. GBD 2021 US Burden of Disease and Forecasting Collaborators. Lancet. 2024 Dec 7;404(10469):2341-2370. doi: 10.1016/S0140-6736(24)02246-3. Lancet. 2024. PMID: 39645377
INTERPRETATION: Our findings highlight the alarming trajectory of health challenges in the USA, which, if left unaddressed, could lead to a reversal of the health progress made over the past three decades for some US states and a decline in global health standing for all s …
INTERPRETATION: Our findings highlight the alarming trajectory of health challenges in the USA, which, if left unaddressed, could lea …
Pharmacogenomics of Preeclampsia therapies: Current evidence and future challenges for clinical implementation.
Chaemsaithong P, Biswas M, Lertrut W, Warintaksa P, Wataganara T, Poon LC, Sukasem C. Chaemsaithong P, et al. Best Pract Res Clin Obstet Gynaecol. 2024 Feb;92:102437. doi: 10.1016/j.bpobgyn.2023.102437. Epub 2023 Nov 25. Best Pract Res Clin Obstet Gynaecol. 2024. PMID: 38103508 Free article. Review.
No current prescribing guidelines from the clinical pharmacogenetics implementation consortium (CPIC) exist for preeclampsia. Although more studies on pharmacogenomics are underway, there is some evidence for the pharmacogenomics of preeclampsia …
No current prescribing guidelines from the clinical pharmacogenetics implementation consortium (CPIC) exist for preecla …
Pharmacogenomics of Drug Hypersensitivity: Technology and Translation.
Kuruvilla R, Scott K, Pirmohamed SM. Kuruvilla R, et al. Immunol Allergy Clin North Am. 2022 May;42(2):335-355. doi: 10.1016/j.iac.2022.01.006. Epub 2022 Mar 31. Immunol Allergy Clin North Am. 2022. PMID: 35469622 Review.
Predisposition seems to be mediated by genetic factors, particularly within the HLA system. Apart from HLA-B57:01 testing, which is routine to prevent abacavir hypersensitivity, uptake of HLA testing into clinical practice has been slow and challenging. As ge …
Predisposition seems to be mediated by genetic factors, particularly within the HLA system. Apart from HLA-B57:01 testing, which is r …
Implementing Precision Medicine: The Ethical Challenges.
Korngiebel DM, Thummel KE, Burke W. Korngiebel DM, et al. Trends Pharmacol Sci. 2017 Jan;38(1):8-14. doi: 10.1016/j.tips.2016.11.007. Epub 2016 Dec 7. Trends Pharmacol Sci. 2017. PMID: 27939182 Free PMC article. Review.
Precision medicine aims to individualize care by understanding differences in genetics, lifestyle, and environment. Pharmacogenomics and cancer genetics represent two promising areas for this approach. ...Similarly, tests to identify people with an inherited …
Precision medicine aims to individualize care by understanding differences in genetics, lifestyle, and environment. Pharmacogenomi
Perspectives of Pediatric Providers Regarding Clinical Use of Pharmacogenetics.
Avello K, Bell M, Stein Q, Bares V, Landsverk M, Salyakina D, McCafferty-Fernandez J, Kingsmore S, Bedrick A, Bhojwani D, Hoyme HE. Avello K, et al. S D Med. 2021 Jul;74(7):294-301. S D Med. 2021. PMID: 34449988
INTRODUCTION: A major goal of the current personalized medicine era is to utilize pharmacogenetics (PGx) in order to influence how medications and therapies are prescribed by providers. ...Additionally, participants identified specific barriers towards the utilization of P …
INTRODUCTION: A major goal of the current personalized medicine era is to utilize pharmacogenetics (PGx) in order to influence how me …
Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting.
Silva P, Jacobs D, Kriak J, Abu-Baker A, Udeani G, Neal G, Ramos K. Silva P, et al. J Pers Med. 2021 May 21;11(6):443. doi: 10.3390/jpm11060443. J Pers Med. 2021. PMID: 34063850 Free PMC article.
The utility of the approach was validated in a virtual patient case showing detection of significant drug-gene and drug-drug interactions of clinical significance. ...Our integrated informatic and bioanalytic platform can provide facile clinical decision supp …
The utility of the approach was validated in a virtual patient case showing detection of significant drug-gene and drug-drug interact …
Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation.
Tan Y, Hu Y, Liu X, Yin Z, Chen XW, Liu M. Tan Y, et al. Methods. 2016 Nov 1;110:14-25. doi: 10.1016/j.ymeth.2016.07.023. Epub 2016 Jul 30. Methods. 2016. PMID: 27485605 Review.
With the same goal of improving drug safety, this article summarizes and links the research efforts in the multiple disciplines into a single framework from comprehensive understanding of the interactions between drugs and biological system and the identification of geneti …
With the same goal of improving drug safety, this article summarizes and links the research efforts in the multiple disciplines into a singl …
The IGNITE network: a model for genomic medicine implementation and research.
Weitzel KW, Alexander M, Bernhardt BA, Calman N, Carey DJ, Cavallari LH, Field JR, Hauser D, Junkins HA, Levin PA, Levy K, Madden EB, Manolio TA, Odgis J, Orlando LA, Pyeritz R, Wu RR, Shuldiner AR, Bottinger EP, Denny JC, Dexter PR, Flockhart DA, Horowitz CR, Johnson JA, Kimmel SE, Levy MA, Pollin TI, Ginsburg GS; IGNITE Network. Weitzel KW, et al. BMC Med Genomics. 2016 Jan 5;9:1. doi: 10.1186/s12920-015-0162-5. BMC Med Genomics. 2016. PMID: 26729011 Free PMC article.
BACKGROUND: Patients, clinicians, researchers and payers are seeking to understand the value of using genomic information (as reflected by genotyping, sequencing, family history or other data) to inform clinical decision-making. However, challenges exist to widespre …
BACKGROUND: Patients, clinicians, researchers and payers are seeking to understand the value of using genomic information (as reflected by g …
Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
Rosenman MB, Decker B, Levy KD, Holmes AM, Pratt VM, Eadon MT. Rosenman MB, et al. Value Health. 2017 Jan;20(1):54-59. doi: 10.1016/j.jval.2016.08.727. Epub 2016 Oct 21. Value Health. 2017. PMID: 28212969 Free PMC article.
CHALLENGES: We placed the clinical pharmacogenomics implementation challenges into six categories: patient education and engagement in care decision making; clinician education and changes in standards of care; integration of techn
CHALLENGES: We placed the clinical pharmacogenomics implementation challenges into six categories: patien
12 results